BioTheryX, Inc. renews its confidence with INOVOTION for preclinical in vivo efficacy evaluation of their compounds.
For BioTheryX, Inc., a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, 2020 has been a fruitful year! The company launched a Phase 1 Clinical Trial of BTX-A51 in January and announced a $35 Million Series D financing in July. We are proud to contribute to BioTheryX, Inc. preclinical efforts!
Leah Fung, PhD, Head of Medicinal Chemistry
"We have found over the past few months and after several projects that INOVOTION’s CAM model is a cost-effective and rapid way to evaluate in vivo efficacy and toxicity of our small molecule #oncology candidates. INOVOTION took the time to understand our project needs and their experienced R&D team worked with us on project design and validation."
Aparajita Hoskote Chourasia, MS, PhD, Associate Director, Biology
"INOVOTION’s data reporting is very detailed and their project management team was always available to make necessary adjustments, discuss results in detail and design potential future steps. We appreciate the timeliness with which they completed our projects, the responsiveness of their communications. They are always ready to accommodate special requests."
If you also wish to collaborate with us, please, feel free to contact us.